glp-1 obesity drug news today How Supply and Demand for Weight Loss Drugs is Playing Out in 2026 New Guidelines on GLP-1 Drugs
Description
2024;384:q642
doi: 10.3390/ijms231911384 148 LiYXuJLiLBaiLWangYZhangJet al
This systematic review of low-to-moderate evidence on the GLP-1 user risk of perioperative regurgitation and aspiration will examine the ongoing challenges in developing evidence-based clinical guidelines for patients using GLP-1 RAs, particularly with respect to perioperative management
[DOI] [PMC free article] [PubMed] [Google Scholar] 39.Semaglutide and cardiovascular outcomes in obesity without diabetes
doi: 10.1016/0167-0115(95)00167-0
Improved metabolic status enhances GnRH frequency and amplitude
